The Evaluation of Oxidative Stress Parameters in Serum Patients with Relapsing-Remitting Multiple Sclerosis Treated with II-Line Immunomodulatory Therapy
Table 4
(a) The comparison of the parameters of oxidative stress in serum in the study groups
Group
De novo RRMS
INF
FG
NT
Control
N
24
33
39
26
41
LHP (μmol/l)
24.64 ± 40.64
3.37 ± 16.32
3.07 ± 7.72
3.99 ± 7.05
0.84 ± 0.62
0.000
MDA (μmol/l)
6.31 ± 3.18
3.11 ± 3.83
3.39 ± 1.75
3.63 ± 2.15
2.56 ± 0.51
0.000
TOS (μmol/l)
39.11 ± 64.51
5.35 ± 35.47
8.48 ± 11.59
6.87 ± 15.4
2.39 ± 1.08
0.000
LPS (RF)
950.47
869.3 ± 293.9
808.52 ± 247.59
745.71 ± 260.59
764 ± 167.77
0.021
(b) Post hoc analysis in the study groups
Parameter
LHP
MDA
TOS
LPS
Group
FG
NT
FG
NT
FG
NT
FG
NT
De novo RRMS
NS
INF
NS
NS
NS
NS
NS
NS
NS
NS
Control
NS
NS
NS
NS
NS
NS
(c) Post hoc analysis in the study groups
Parameter
LHP
MDA
TOS
LPS
Group
INF
Control
INF
Control
INF
Control
INF
Control
De novo RRMS
NS
Control
x
x
x
NS
x
De novo RRMS: patients with a new diagnosed relapsing-remitting multiple sclerosis; RRMS INF: RRMS patients treated with interferon beta; FG: RRMS patients treated with fingolimod; NT: RRMS patients treated with natalizumab; LHP: lipid hydroxyperoxides; MDA: malondialdehyde; TOS: total oxidative status; LPS: lipofuscin; NA: nonapplicable; statistical significance for .
